Partow Kebriaei on Monitoring Patients for Cytokine Release Syndrome


Partow Kebriaei, MD, from MD Anderson Cancer Center, discusses how nurses can monitor patients for cytokine release syndrome.

Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses what to be aware of when treating patients who have undergone CAR T-cell therapies.

Cytokine release syndrome (CRS) and other neurotoxicities often occur within the first 2 weeks after infusion of CAR T-cell therapy. During this time, symptoms such as fever may not seem alarming but can be indications of CRS. It is important to carefully monitor these patients through vitals, daily weight, and mental status. Close observation during the first weeks after the CAR T-cell therapy is necessary to catch CRS in these patients.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, in an interview with Oncology Nursing News
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.